- Home
- RHI vs CDTX Comparison
RHI vs CDTX Comparison
Compare RHI & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RHI | CDTX |
|---|---|---|
| Founded | 1948 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RHI | CDTX |
|---|---|---|
| Price | $27.18 | $219.76 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $40.00 | ★ $119.44 |
| AVG Volume (30 Days) | ★ 2.8M | 2.1M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $5,458,499,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.22 | $15.22 |
| 52 Week High | $78.41 | $220.46 |
Technical Indicators
Market Signals| Indicator | RHI | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 88.62 |
| Support Level | $26.77 | $218.86 |
| Resistance Level | $27.85 | $220.46 |
| Average True Range (ATR) | 1.06 | 2.38 |
| MACD | 0.35 | 5.08 |
| Stochastic Oscillator | 61.42 | 99.41 |
Price Performance
Historical ComparisonAbout RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.